Hepatitis C New Drugs Review
21.7K views | +9 today
Follow
 
Scooped by Krishan Maggon
onto Hepatitis C New Drugs Review
Scoop.it!

Gilead Races Against Competitors for an Oral Hepatitis-C Cure - Motley Fool

Gilead Races Against Competitors for an Oral Hepatitis-C Cure
Motley Fool
Vertex hopes to follow up its highly successful Incivek with another all-oral option.
more...
No comment yet.
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The 2016 Lasker Awards: Hepatitis C Virus—From Discovery to Cure

The 2016 Lasker Awards: Hepatitis C Virus—From Discovery to Cure | Hepatitis C New Drugs Review | Scoop.it
Opinion from JAMA — Hepatitis C Virus—From Discovery to Cure — The 2016 Lasker-DeBakey Clinical Medical Research Award

In this Viewpoint, 2016 Lasker Award winners Ralf Bartenschlager, Charles Rice, and Michael Sofia discuss their work developing a system to study the replication of hepatitis C virus and a class of antivirals to treat the infection. The liver is the largest organ in the human body and is central for metabolism and many other functions. Several viruses specialize in infecting the liver and are called hepatitis viruses. Five such viruses are known, including hepatitis C virus (HCV), which was originally recognized as an agent of posttransfusion non-A, non-B hepatitis. Given that about 6% of patients receiving blood transfusions developed non-A, non-B hepatitis, tremendous efforts were mounted to isolate and molecularly clone this filterable agent, likely a virus.
Krishan Maggon 's insight:
Hepatitis C Virus—From Discovery to Cure The 2016 Lasker-DeBakey Clinical Medical Research Award Ralf F. W. Bartenschlager, PhD1; Charles M. Rice, PhD2; Michael J. Sofia, PhD3 
September 27, 2016, Vol 316, No. 12 
JAMA. 2016;316(12):1254-1255. doi:10.1001/jama.2016.13713.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4

Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4 | Hepatitis C New Drugs Review | Scoop.it
(2016). Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Review of Clinical Pharmacology. Ahead of Print. doi: 10.1080/17512433.2016.1233813

Elbasvir/grazoprevir combination showed great efficacy with high rates of sustained virological response rates in genotypes 1 and 4 HCV infection. In addition, it retained a good safety profile and is generally well tolerated.
Krishan Maggon 's insight:
http://dx.doi.org/10.1080/17512433.2016.1233813

Mohamed El Kassas, Tamer Elbaz, Yasmeen Abd El Latif & Gamal Esmat
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Treatment Panel Calls For Hepatitis B Testing

Hepatitis C Treatment Panel Calls For Hepatitis B Testing | Hepatitis C New Drugs Review | Scoop.it
Hepatitis B and C are caused by different viruses that can start as acute infections but turn chronic in some people and eventually lead to life-threatening liver damage, according to the Centers for Disease Control and Prevention.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Efficacy and Safety of Sofosbuvir with Simeprevir in Hepatitis C Infected Patients with Severe Chronic Kidney Disease: A Systematic Review and Meta-Analysis | BEMS Reports

Efficacy and Safety of Sofosbuvir with Simeprevir in Hepatitis C Infected Patients with Severe Chronic Kidney Disease: A Systematic Review and Meta-Analysis | BEMS Reports | Hepatitis C New Drugs Review | Scoop.it
Efficacy and Safety of Sofosbuvir/ Simeprevir in Hepatitis C Infected Patients with Severe Chronic Kidney Disease https://t.co/Tmk9mH4RWX
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Can-Fite An Emerging NASH Play With CF102

Can-Fite An Emerging NASH Play With CF102 | Hepatitis C New Drugs Review | Scoop.it
NASDAQ:CANF, Can-Fite, BioNap, JNapodano, Napodano, #NASH, CF102
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Nature Reviews Gastroenterology & Hepatology - Table of Contents alert Volume 13 Issue 10

Nature Reviews Gastroenterology & Hepatology - Table of Contents alert Volume 13 Issue 10 | Hepatitis C New Drugs Review | Scoop.it
If you are unable to see the message below, click here to view . Advertisement Covering the evolution of science since 1869
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma | Qi | Oncotarget

Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma | Qi | Oncotarget | Hepatitis C New Drugs Review | Scoop.it
Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients

Medivir: Updated Interim Phase IIa Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL-335 Has a High Level of Efficacy in HCV Patients | Hepatitis C New Drugs Review | Scoop.it
Medivir AB (STO:MVIRB) today announced that updated interim data from a phase IIa study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen), were presented on September 23rd at the European Association for the Study of the Liver (EASL) Special Conference in Paris, France.
Krishan Maggon 's insight:
Based on the interim data from this study, the triple combination of simeprevir 75mg QD, odalasvir 25mg QD and AL-335 400mg QD has been selected for further development. The development program for the triple combination will include a multi-center, randomized, open-label study that will enroll treatment-naive and treatment-experienced non-cirrhotic patients chronically infected with hepatitis C virus genotypes 1, 2, 4, 5, and 6. In addition, the ongoing phase IIa study is assessing the triple combination in patients with or without compensated cirrhosis, and with HCV genotype 3 infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

EASL Recommendations on Treatment of Hepatitis C 2016

EASL Recommendations on Treatment of Hepatitis C 2016 | Hepatitis C New Drugs Review | Scoop.it
RT @JHepatology: EASL Recommendations on Treatment of Hepatitis C 2016
https://t.co/zjeDd06OCp
#HCV #HepC #HepatitisC https://t.co/ZI1aAPvB…

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC). The number of chronically infected persons worldwide is estimated to be about 180 million [2], but most are unaware of their infection. Clinical care for patients with HCV-related liver disease has advanced considerably during the last two decades, thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Clinical and Translational Gastroenterology - Hepatitis C Treatment and Barriers to Eradication

Clinical and Translational Gastroenterology - Hepatitis C Treatment and Barriers to Eradication | Hepatitis C New Drugs Review | Scoop.it
Brought to you by the American College of Gastroenterology.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Targeting Cardio-Metabolic Diseases: A focus on Liver Fibrosis and NASH Targets at CHI’s 14th Discovery Targets

Targeting Cardio-Metabolic Diseases: A focus on Liver Fibrosis and NASH Targets at CHI’s 14th Discovery Targets | Hepatitis C New Drugs Review | Scoop.it
LIVE 9/21 8AM to 2:40PM Targeting Cardio-Metabolic Diseases: A focus on Liver Fibrosis and NASH Targets at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston http://www.discoveryontarget.com/ http://www.discoveryontarget.com/crispr-therapies/...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Akarna Therapeutics FXR Agonists NASH

Akarna Therapeutics FXR Agonists NASH | Hepatitis C New Drugs Review | Scoop.it
NASH and FXR Accumulation of lipids (steatosis) within the liver cells (hepatocytes) leads to fatty liver disease, which is followed by chronic liver inflammation and liver fibrosis resulting in progression of fatty liver disease to NASH. FXR plays a key role in regulating each of these stages of NASH.
Krishan Maggon 's insight:
FXR agonists reduce lipid accumulation
FXR agonists reduce inflammation
FXR agonists block the progression of fibrosis

Akarna is  developing small molecule, non-bile acid FXR agonist drugs and has been acquired by Allergan
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gilead Sciences: Are Hepatitis C Sales Improving?

Gilead Sciences: Are Hepatitis C Sales Improving? | Hepatitis C New Drugs Review | Scoop.it
Citigroup's Robyn Karnauskas notes that Gilead Sciences' (GILD) hepatitis C prescriptions are "still below consensus but new starts contribute to improvement." She explains:
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Galectin Therapeutics lead GR-MD-02 fails Exploratory Phase 2a Pilot Trial in NASH Patients with Advanced Fibrosis 

Galectin Therapeutics lead GR-MD-02 fails Exploratory Phase 2a Pilot Trial in NASH Patients with Advanced Fibrosis  | Hepatitis C New Drugs Review | Scoop.it

NORCOSS, Ga., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced topline results from NASH-FX, its Phase 2a clinical trial evaluating the efficacy, safety, and tolerability of GR-MD-02 in 30 nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis. This exploratory, single site, short-treatment (four months of therapy), randomized study did not meet its primary biomarker endpoint as measured by LiverMultiScan (LMS, Perspectum Diagnostics), a magnetic resonance imaging test that evaluates inflammation and fibrosis. The trial also did not meet secondary endpoints that measure liver stiffness as a surrogate for fibrosis, with FibroScan® and magnetic resonance elastography (MRE). While all patients had a baseline liver biopsy to establish the diagnosis and fibrosis severity, liver biopsies were not performed at the end of the study following treatment due to safety considerations involved with liver biopsy-related risk in a short duration trial. GR-MD-02 was found to be safe and well tolerated among the patient population with no serious adverse events. 


Importantly, Galectin simultaneously announced that the principal focus of its research efforts—its larger scale, one-year, multi-site trial in patients with NASH cirrhosis (NASH-CX)—has completed enrollment one month early with 162 total subjects (exceeding the target of 156 patients), allowing for reporting of top-line results in December 2017. In further contrast to the NASH-FX trial, the NASH-CX trial is being conducted with a primary endpoint (hepatic venous pressure gradient (HVPG)) which the U.S. Food and Drug Administration may view as an acceptable surrogate for outcomes for registration trials in this patient population.

Krishan Maggon 's insight:
GR-MD-02 is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. Galectin-3 plays a major role in diseases that involve scarring of organs including fibrotic disorders of the liver, lung, kidney, heart and vascular system. The drug binds to galectin proteins and disrupts their function. Preclinical data in animals have shown that GR-MD-02 has robust treatment effects in reversing liver fibrosis and cirrhosis.

Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled 


more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

AbbVie’s 8 week trial speedy and successful for 98% of Hep C patients

AbbVie’s 8 week trial speedy and successful for 98% of Hep C patients | Hepatitis C New Drugs Review | Scoop.it
The primary endpoint of the trial being the percentage of patients who achieved a sustained virologic response 12 weeks after treatmen
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Leveraging the liver’s ability to heal scarred tissue | Novartis Institutes for BioMedical Research

Leveraging the liver’s ability to heal scarred tissue | Novartis Institutes for BioMedical Research | Hepatitis C New Drugs Review | Scoop.it
RT @NovartisScience: Read more about NIBR’s research into the liver’s unusual regenerative properties: https://t.co/yGp8HvDRWO https://t.co
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV - HepCBC

Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV - HepCBC | Hepatitis C New Drugs Review | Scoop.it
– Ongoing Phase 2 development focusing on triple combination for treatment durations as short as six weeks for broad HCV population – PARIS, Sept. 23, 2016 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

AbbVie VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets)  Eight-Week Treatment SVR 98% in Genotype 1b Chronic Hepatitis C 

AbbVie VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets)  Eight-Week Treatment SVR 98% in Genotype 1b Chronic Hepatitis C  | Hepatitis C New Drugs Review | Scoop.it
NORTH CHICAGO, Ill., Sept. 23, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data showing high response rates with just eight weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) treatment. In the Phase 3b GARNET study, 98 percent (n=160/163) of previously untreated patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection without cirrhosis achieved sustained virologic response rates at 12 weeks post-treatment (SVR12).1 These data were presented today at the 2016 EASL Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure, in Paris, France and included in the newly published 'EASL Recommendations on Treatment of Hepatitis C.' VIEKIRAX + EXVIERA is currently approved in the European Union for GT1b patients without cirrhosis or with compensated cirrhosis for 12 weeks.
Krishan Maggon 's insight:
98 percent of previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVR12 in Phase 3b GARNET study1 - First study evaluating 8 weeks of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets)1

GT1b is the most common subtype globally,2 accounting for 47 percent of the nine million people infected with chronic HCV in Europe alone3,4 

- GARNET study results on 8-week treatment duration included in newly published 'EASL Recommendations on Treatment of Hepatitis C'
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Drug Users on Direct-Acting Virals Need Help to Complete Hep C Regimens

Drug Users on Direct-Acting Virals Need Help to Complete Hep C Regimens | Hepatitis C New Drugs Review | Scoop.it
Even when people inject drugs have access to direct-acting antivirals for hepatitis C infection there can be barriers to getting them to complete their drug regimens.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

How Gilead Dominates the HCV Space - Market Realist

How Gilead Dominates the HCV Space - Market Realist | Hepatitis C New Drugs Review | Scoop.it
In January 2012, Gilead Sciences (GILD) acquired Pharmasset and got access to sofosbuvir. In December 2013, the FDA approved sofosbuvir under the brand name Sovaldi.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Mayo Clinic researchers update understanding of damaging liver disease

Mayo Clinic researchers update understanding of damaging liver disease | Hepatitis C New Drugs Review | Scoop.it
ROCHESTER, Minn. — An article published today in the New England Journal of Medicine updates the medical community on a potentially d…
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence

Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence | Hepatitis C New Drugs Review | Scoop.it
(2016). Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence. Expert Review of Gastroenterology & Hepatology. Ahead of Print.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer

Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer | Hepatitis C New Drugs Review | Scoop.it
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, yet no effective therapeutics exist.

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, yet no effective therapeutics exist. This review provides an overview of the recent development of recombinant immunotoxins for the treatment of glypican-3 (GPC3) expressing HCC. GPC3 is a cell surface heparan sulfate proteoglycan that is overexpressed in HCC, but is absent from normal adult human tissues. Treatment of HCC with anti-GPC3 immunotoxins represents a new therapeutic option. Using phage display and hybridoma technologies, three high affinity antibodies (HN3, HS20 and YP7) have been generated against GPC3. Two of these antibodies (HN3 and HS20) have demonstrated the ability to inhibit Wnt/Yap signaling, leading to a reduction in liver cancer cell proliferation. By combining the HN3 antibody capable of inhibiting Wnt/Yap signaling with the protein synthesis inhibitory domain of the Pseudomonas exotoxin, a recombinant immunotoxin that exhibits a dual inhibitory mechanism was generated. This immunotoxin was found to be highly effective in the treatment of human HCCs in mouse xenograft models. Engineering of the toxin fragment to reduce the level of immunogenicity is currently being explored. The development of immunotoxins provides opportunities for novel liver cancer therapies. 

Keywords: recombinant immunotoxin; glypican-3 (GPC3); hepatocellular carcinoma; liver cancer; monoclonal antibodies; pseudomonas exotoxin
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Allergan: Examining The Premiums Paid

Allergan: Examining The Premiums Paid | Hepatitis C New Drugs Review | Scoop.it
Allergan acquires Tobira Therapeutics for +$1B to gain entry into the NASH market.Tobira's leading drug candidate can serve as a cornerstone for Allergan's new
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Big Pharma, Biotech Attack NASH Liver Illness From All Sides

Big Pharma, Biotech Attack NASH Liver Illness From All Sides | Hepatitis C New Drugs Review | Scoop.it
It’s been called a “silent epidemic” that’s slowly wasting away the livers of millions of Americans while doctors have a paltry understanding of the disease and no approved treatments.

Non-alcoholic steatohepatitis, or NASH, is now in the sights of more than a dozen drugmakers. Allergan Plc became the latest Tuesday. It announced two deals in less than 12 hours to acquire companies developing NASH treatments, including Tobira Therapeutics Inc. for as much as $1.7 billion in what Chief Executive Officer Brent Saunders said Wednesday was a “very competitive situation.” 

Allergan is racing companies ranging from startup Intercept Pharmaceuticals Inc. to giants including Gilead Sciences Inc. and Pfizer Inc. to reach an untapped market that could be worth $5 billion to $10 billion a year, according to a May estimate by RBC Capital Markets Corp. analyst Michael Yee.
more...
No comment yet.